Procalcitonin in early onset ventilator-associated pneumonia

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Biomarker Research

Background:

• Ventilator-associated pneumonia (VAP) presents a significant challenge in intensive care settings.
• There is a critical need for reliable biomarkers to guide VAP management.
• Procalcitonin (PCT) has emerged as a potential biomarker for bacterial infections.

Purpose of the Study:

• To evaluate the clinical utility of monitoring procalcitonin (PCT) levels in non-surgical patients diagnosed with early-onset VAP.
• To determine if PCT concentrations can predict outcomes such as mortality and septic shock.

Main Methods:

• A cohort of 34 non-surgical patients with early-onset VAP (diagnosed 48 hours to 6 days after mechanical ventilation initiation) was studied.
• Serum PCT levels were measured serially on days 1, 2, 3, 5, 6, and 7 post-diagnosis.
• Statistical analyses included receiver operator curve (ROC) analysis to assess predictive values for mortality and septic shock.

Main Results:

• The overall mortality rate in the study cohort was 21%.
• Non-survivors exhibited significantly elevated PCT levels on days 3 and 7, with AUCs of 0.762 and 0.754, respectively.
• In septic patients, PCT was significantly higher on multiple days, with a day 1 cut-off of 1 ng/mL showing a positive predictive value of 0.813 for septic shock development.

Conclusions:

• Procalcitonin (PCT) levels were not associated with the effectiveness of antibiotic treatment or the specific cause of VAP.
• PCT concentration did not significantly correlate with poor patient outcomes in logistic regression analysis.
• While higher PCT levels were observed in non-survivors and those who developed septic shock, PCT alone is not a robust predictor of these critical events.